EP Patent

EP3826638A1 — Elagolix sodium compositions and processes

Assigned to AbbVie Inc · Expires 2021-06-02 · 5y expired

What this patent protects

The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.

USPTO Abstract

The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.

Drugs covered by this patent

Patent Metadata

Patent number: EP3826638A1
Jurisdiction: EP
Classification: —
Expires: 2021-06-02
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.